News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
207,222 Results
Type
Article (19737)
Company Profile (104)
Press Release (187381)
Multimedia
Podcasts (29)
Webinars (9)
Section
Business (65753)
Career Advice (819)
Deals (9551)
Drug Delivery (73)
Drug Development (19403)
Employer Resources (140)
FDA (3507)
Job Trends (6046)
News (98623)
Policy (7406)
Tag
2024 BioForest Digital (2)
2024 BioForest Standard (1)
2024 BioMidwest Digital (3)
2024 BioMidwest Standard (2)
2024 Bio NC Digital (6)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (9)
2024 Biotech Beach Digital (3)
2024 Biotech Beach Standard (6)
2024 Genetown Standard (4)
2024 Lone Star Bio Digital (1)
2024 Pharm Country Digital (2)
2024 Pharm Country Standard (5)
2025 Lone Star Bio Digital (2)
2026 BioCapital Elite (1)
2026 BioMidwest Elite (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (1)
2026 Pharm Country Standard (1)
Academia (1505)
Academic (2)
Accelerated approval (1)
Adcomms (16)
Allergies (18)
Alliances (18370)
ALS (29)
Alzheimer's disease (548)
Antibody-drug conjugate (ADC) (57)
Approvals (3509)
Artificial intelligence (124)
Autoimmune disease (9)
Automation (8)
Bankruptcy (50)
Best Places to Work (4929)
BIOSECURE Act (11)
Biosimilars (50)
Biotechnology (64)
Bladder cancer (23)
Brain cancer (6)
Breast cancer (90)
Cancer (619)
Cardiovascular disease (61)
Career advice (723)
Career pathing (30)
CAR-T (52)
Cell therapy (145)
Cervical cancer (8)
Clinical research (14854)
Collaboration (369)
Compensation (89)
Complete response letters (7)
COVID-19 (978)
CRISPR (19)
C-suite (124)
Cystic fibrosis (40)
Data (618)
Decentralized trials (1)
Denatured (21)
Depression (16)
Diabetes (66)
Diagnostics (2435)
Digital health (5)
Diversity (7)
Diversity, equity & inclusion (37)
Drug discovery (52)
Drug pricing (44)
Drug shortages (5)
Duchenne muscular dystrophy (39)
Earnings (15154)
Editorial (13)
Employer branding (23)
Employer resources (118)
Events (30225)
Executive appointments (380)
FDA (3830)
Featured Employer (33)
Friedreich's ataxia (1)
Frontotemporal dementia (3)
Funding (350)
Gene editing (38)
Generative AI (14)
Gene therapy (100)
GLP-1 (300)
Government (1329)
Guidances (18)
Healthcare (5157)
Huntington's disease (13)
IgA nephropathy (8)
Immunology and inflammation (26)
Indications (5)
Infectious disease (1033)
Inflammatory bowel disease (57)
Inflation Reduction Act (7)
Influenza (15)
Intellectual property (29)
Interviews (116)
IPO (3763)
IRA (16)
Job creations (1322)
Job search strategy (633)
Kidney cancer (1)
Labor market (32)
Layoffs (159)
Leadership (10)
Legal (1306)
Liver cancer (23)
Lung cancer (95)
Lymphoma (52)
Machine learning (1)
Management (42)
Manufacturing (123)
MASH (12)
Medical device (2737)
Medtech (2741)
Mergers & acquisitions (6019)
Metabolic disorders (202)
Multiple sclerosis (37)
NASH (9)
Neurodegenerative disease (26)
Neuropsychiatric disorders (4)
Neuroscience (730)
NextGen: Class of 2025 (2103)
Non-profit (1670)
Northern California (791)
Now hiring (36)
Obesity (126)
Opinion (96)
Ovarian cancer (22)
Pain (32)
Pancreatic cancer (12)
Parkinson's disease (42)
Partnered (13)
Patents (50)
Patient recruitment (22)
Peanut (13)
People (27408)
Pharmaceutical (26)
Pharmacy benefit managers (1)
Phase I (4398)
Phase II (6157)
Phase III (5837)
Pipeline (306)
Policy (53)
Postmarket research (590)
Preclinical (2452)
Press Release (61)
Prostate cancer (26)
Psychedelics (18)
Radiopharmaceuticals (68)
Rare diseases (124)
Real estate (2608)
Recruiting (54)
Regulatory (5336)
Reports (36)
Research institute (1270)
Resumes & cover letters (106)
Rett syndrome (1)
RNA editing (1)
RSV (24)
Schizophrenia (22)
Series A (72)
Series B (40)
Service/supplier (8)
Sickle cell disease (23)
Southern California (552)
Special edition (8)
Spinal muscular atrophy (51)
Sponsored (13)
Startups (2033)
State (1)
Stomach cancer (6)
Supply chain (23)
Tariffs (4)
The Weekly (8)
United States (6756)
Vaccines (195)
Venture capitalists (27)
Weight loss (88)
Women's health (12)
Worklife (15)
Date
Today (48)
Last 7 days (166)
Last 30 days (816)
Last 365 days (10705)
2025 (2985)
2024 (11695)
2023 (13328)
2022 (16904)
2021 (18823)
2020 (17041)
2019 (15449)
2018 (11080)
2017 (10697)
2016 (10477)
2015 (11365)
2014 (8408)
2013 (7281)
2012 (7751)
2011 (7878)
2010 (7329)
Location
Africa (326)
Alabama (21)
Alaska (4)
Arizona (66)
Arkansas (4)
Asia (11580)
Australia (2112)
California (1675)
Canada (623)
China (137)
Colorado (88)
Connecticut (63)
Delaware (74)
Europe (32540)
Florida (252)
Georgia (54)
Hawaii (1)
Idaho (12)
Illinois (130)
India (17)
Indiana (141)
Iowa (5)
Japan (68)
Kansas (27)
Kentucky (7)
Louisiana (4)
Maine (6)
Maryland (199)
Massachusetts (1395)
Michigan (94)
Minnesota (109)
Mississippi (1)
Missouri (31)
Montana (4)
Nebraska (9)
Nevada (11)
New Hampshire (13)
New Jersey (556)
New Mexico (16)
New York (638)
North Carolina (327)
North Dakota (7)
Northern California (791)
Ohio (63)
Oklahoma (6)
Oregon (15)
Pennsylvania (323)
Puerto Rico (3)
Rhode Island (8)
South America (401)
South Carolina (5)
Southern California (552)
Tennessee (31)
Texas (219)
Utah (48)
Virginia (42)
Washington D.C. (22)
Washington State (140)
Wisconsin (32)
207,222 Results for "roivant sciences gmbh".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Startups
Roivant Creates New ‘Vant’ to License Bayer’s Pulmonary Hypertension Drug
Under an in-license agreement worth up to $294 million, Roivant Sciences gains exclusive worldwide rights from Bayer to develop and commercialize mosliciguat, a potential first-in-class inhaled soluble guanylate cyclase activator.
September 10, 2024
·
2 min read
·
Tristan Manalac
M&A
Roivant Deals Again, Sending Dermavant to Organon in Sale Worth Up to $1.2B
The sale of Dermavant clears the way for Roivant to focus on autoimmune-focused Immunovant and a slate of upcoming pivotal trials.
September 18, 2024
·
3 min read
·
Annalee Armstrong
Press Releases
Roivant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies
March 19, 2025
·
13 min read
Press Releases
Roivant Reports Financial Results for the Third Quarter Ended December 31, 2024, and Provides Business Update
February 10, 2025
·
17 min read
Drug Development
Roivant and Kinevant Sciences Complete Enrollment in RESOLVE-Lung, a Phase 2 Study Evaluating Namilumab for Chronic Pulmonary Sarcoidosis
Roivant (Nasdaq: ROIV) and Kinevant Sciences, a clinical-stage biopharmaceutical company developing new medicines for rare inflammatory and autoimmune diseases, today announced the successful completion of enrollment in its Phase 2 study evaluating namilumab for the treatment of chronic pulmonary sarcoidosis (RESOLVE-Lung).
April 25, 2024
·
6 min read
Press Releases
Zymo Research Responds to Recent Court Ruling in Litigation with QIAGEN GmbH
March 19, 2025
·
1 min read
Press Releases
Roivant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs
March 18, 2025
·
1 min read
Press Releases
Scipher Medicine and Roivant Partner to Bring Precision Medicine Insights to Rheumatology Drug Discovery and Development
January 13, 2025
·
2 min read
Press Releases
Roivant to Report Financial Results for the Third Quarter Ended December 31, 2024 and Provide Business Update on Monday, February 10, 2025
January 30, 2025
·
4 min read
Business
Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provides Business Update
Roivant (Nasdaq: ROIV) today reported its financial results for the fourth quarter and fiscal year ended March 31, 2024, and provided a business update.
May 30, 2024
·
21 min read
1 of 20,723
Next
